- In April 2024, Takeda Pharmaceutical Company likely continued its strong performance in albumin products, as indicated by their Q4 2024 financial results, which reported growth in Plasma-Derived Therapies, including albumin products such as HUMAN ALBUMIN and FLEXBUMIN. This suggests ongoing market focus and potentially new initiatives related to these therapies
- In March 2024, BPL (Biotechnology Products Laboratories) launched an albumin-based drug delivery system aimed at enhancing the bioavailability of hydrophobic drugs. This advancement highlights the commitment to developing cutting-edge therapeutic technologies that safeguard patient health and ensure greater efficacy for pharmaceutical formulations
- In July 2024, CSL Behring launched a new albumin-based product for drug delivery in cancer treatment, highlighting its growing role in precision medicine. This initiative harnesses state-of-the-art solutions to create more effective and targeted therapies, underscoring CSL Behring's dedication to utilizing its expertise in innovative biopharmaceutical systems
- In December 2023, Albumedix, now part of Sartorius, completed its new state-of-the-art albumin manufacturing facility in the UK. This facility will enable the company to meet increased global demand for high-quality human serum albumin and support future therapeutic development
- In July 2023, Grifols announced the completion of enrollment in its phase-3 trial of Albutein (albumin-human injection) for the treatment of patients with decompensated cirrhosis. This innovative therapeutic effort highlights the company’s commitment to integrating advanced research into clinical solutions, offering healthcare providers enhanced options for managing complex liver conditions and ensuring robust patient care
